Transforming cardiometabolic drug development through precision medicine, translational innovation, and patient stratification.
Your Partner in Precision Medicine Solutions
Transforming Cardiometabolic Patient Outcomes
Claveritas™ is a strategic biopharmaceutical advisory firm focused on accelerating the development of precision medicines for stratified patient populations with cardiometabolic diseases.
We partner with biotechnology and pharmaceutical companies to integrate translational science, clinical development, biomarkers, precision medicine, regulatory strategy, and portfolio planning into cohesive development programs that improve the probability of technical and regulatory success.
Drawing upon decades of leadership experience across discovery research, translational medicine, clinical development, and commercialization, Claveritas™ helps organizations identify the right patients, validate biological mechanisms, develop actionable biomarker strategies, optimize clinical development plans, and generate differentiated evidence to support regulatory approval and market adoption.
Our expertise spans obesity, Type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, inflammatory diseases, and emerging precision medicine approaches designed to deliver the right therapy to the right patient at the right time.
Our mission is to bridge scientific innovation and clinical execution to advance transformative therapies that improve outcomes for patients with complex cardiometabolic diseases.
Publication: The Quagmire of Systemic Inflammation, GLP-1 Genetic Variability, and Precision Therapeutics: Toward a New Era of Stratified Cardiometabolic Medicine (pending)
Publication: The Quagmire of Systemic Inflammation, GLP-1 Genetic Variability, and Precision Therapeutics: Toward a New Era of Stratified Cardiometabolic Medicine (pending)